Novartis: continued efficacy demonstrated in breast cancer.
(CercleFinance.com) - Novartis today unveiled updated findings from a phase III study that reinforce the efficacy and safety of Kisqali plus letrozole in advanced or metastatic breast cancer.
After an additional 11 months of follow-up, a median progression-free survival (PFS) of 25.3 months for Kisqali plus letrozole was observed, and 16 months for letrozole alone.
After two years of treatment, the progression-free survival rate was 54.7% in the Kisqali plus letrozole arm compared to 35.9% in patients treated with letrozole alone.
The study comprised postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
This data will be presented to the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Sunday 4 June.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
After an additional 11 months of follow-up, a median progression-free survival (PFS) of 25.3 months for Kisqali plus letrozole was observed, and 16 months for letrozole alone.
After two years of treatment, the progression-free survival rate was 54.7% in the Kisqali plus letrozole arm compared to 35.9% in patients treated with letrozole alone.
The study comprised postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
This data will be presented to the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Sunday 4 June.
Copyright (c) 2017 CercleFinance.com. All rights reserved.